BioScrip to Present at Bank of America Merrill Lynch 2017 Leveraged Finance Conference

BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will present at the Bank of America Merrill Lynch 2017 Leveraged Finance Conference on Wednesday, November 29, 2017, at 8:10 a.m. EST.  The conference will be held at the Boca Raton Resort & Club in Boca Raton, FL.

A live webcast of the presentation and copies of the materials presented can be accessed via BioScrip’s Investor Relations website at https://investors.bioscrip.com/events-and-presentations/upcoming-events or through the following link:http://www.veracast.com/webcasts/baml/levfin2017/id22103128559.cfm.

About BioScrip, Inc.

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Investor Contacts:

Stephen Deitsch                                                                               Chief Financial Officer & Treasurer                                        T:  [phone]                                                                        [e-mail]                                                

David ClairICR, Inc.T:  (646) [e-mail]